ABOUT US

Blazar develops software and methods to help biomedical and translational R&D teams structure workflows in which results, model outputs, and supporting evidence remain interpretable, usable, and traceable over time.

Blazar emerged from work in artificial intelligence applied to pathology, biomarkers, and translational modelling, in contexts where results needed to retain their relevance despite changes in data, instruments, pipelines, and conditions of use.

This work brought a recurring difficulty into focus: as workflows evolve, results may retain value, but the conditions required for interpreting, comparing, and using them become more demanding.

Blazar’s early work explored predictive and clinically oriented approaches in oncology research, at a time shaped by the rise of precision medicine and data-driven methods.

It gave the team direct experience of the challenges of heterogeneity, reproducibility, and interpretation in complex biomedical workflows.

It also revealed a broader constraint: the difficulty did not lie only in the absence of sophisticated analytical methods, but in determining to what extent results remained comparable, interpretable, and appropriate for use as methods, protocols, and contexts evolved.

In research and translational environments, results often continue to circulate even after the conditions in which they were produced have evolved. They may retain value, but their meaning, context, and underlying assumptions become less explicit.

Blazar’s current direction is grounded in that observation. We develop software and methods designed to make those conditions more explicit, preserve continuity of interpretation, and support traceability, structured review, and responsible use over time.

We operate within clearly defined scopes and formalised requests, within existing institutional environments and their access constraints. Our approach relies on documented assumptions, structured workflows, and human supervision at every stage.

Partner organisations retain full control over interpretation, decisions, and downstream use.

Blazar does not provide autonomous decisions, diagnostic results, or promises of outcomes. The technologies and solutions described are under research and development and are not intended for clinical use.

Blazar has participated in research, innovation, and support programs, and has been referenced in public communications related to those activities.

The technologies and solutions described are under research and development. They are not CE-marked under Regulation (EU) 2017/745 and are not intended for diagnosis or clinical decision-making.